Electrodiagnostic tests are unlikely to change management in those with a known cause of typical distal symmetric polyneuropathy by Callaghan, Brian C. et al.
A
cc
ep
te
d 
A
rt
ic
le
Financial disclosure- Dr. Callaghan is supported by NIH K23 NS079417 
Conflict of interest- None of the authors has any conflict of interest to disclose relevant to this 
publication. 
Title: Electrodiagnostic tests are unlikely to change management in those with a known cause of 
typical distal symmetric polyneuropathy 
 
 
 
Brian C. Callaghan, M.D., M.S. (1) bcallagh@med.umich.edu 
James F. Burke, M.D., M.S. (1) jamesbur@med.umich.edu 
Kevin A. Kerber, M.D., M.S. (1) kakerber@med.umich.edu 
James W. Albers, M.D., Ph.D. (1) jwalbers@med.umich.edu 
Eva L. Feldman, M.D., Ph.D. (1) efeldman@med.umich.edu 
 
 
 
(1) Department of Neurology, University of Michigan, Ann Arbor 
Word count: 500, References: 5 
Corresponding author: Brian Callaghan 
109 Zina Pitcher Place 
4021 BSRB 
Ann Arbor, MI 48104 
734-764-7205 office 
734-615-7466 fax 
bcallagh@med.umich.edu 
We confirm that we have read the Journal’s position on issues involved in ethical publication and 
affirm that this report is consistent with those guidelines  
  
Page 1 of 4
John Wiley & Sons, Inc.
Muscle & Nerve
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
We read with interest the Issues and Opinions article by Bodofsky et al. summarizing the 
existing evidence and concluding that “the majority of patients who present with new symptoms 
and signs suggestive of distal symmetric polyneuropathy (DSP) should undergo electrodiagnostic 
(EDx) testing.”
1
 However, we interpret the same evidence differently. The authors cite four 
supporting studies and one conflicting study by our group.
2-6
 One of the supporting studies 
included patients with symptoms or signs of chronic polyneuropathy evaluated at an academic 
medical center.
6
 Rosenberg et al. found that 90 of 172 (52%) EDx evaluations contributed to the 
diagnosis in the entire population although they did not evaluate how often management changes 
occurred. However, they also found that 69 of 73 (95%) EDx evaluations of patients with 
polyneuropathy of known cause were considered unnecessary, leading them to conclude: “In 
patients with signs and symptoms of a DSP with duration of more than 6 weeks and a known 
cause”, “confirmation of peripheral neuropathy by neurophysiological studies is unnecessary.” 
Furthermore, two of the other cited studies, while concluding that EDx testing often changes 
management amongst all tertiary electrodiagnostic referrals, contained small numbers of 
suspected polyneuropathy patients (16% and 21% respectively), limiting inferences of the 
benefits of EDx testing in polyneuropathy.
4, 5
 Of note, no standard definition of polyneuropathy 
was used and referring physicians included all provider types. In the last study, Cho et al. 
included 44 patients evaluated at a tertiary EDx laboratory who had a referral diagnosis of DSP 
and paresthesias, dysesthesias, or pain in both feet.
3
 Excluding 8 patients with motor 
predominant symptoms, a red flag indicating an atypical neuropathy, 33% of EDx evaluations 
led to a management change. While this small study supports Bodofsky et al’s conclusion, it has 
important limitations: tertiary setting, lack of a standardized DSP definition, and limited detail of 
management changes. In contrast, our population-based study
2
 included 458 patients seen by 
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community neurologists in Texas and meeting the Toronto consensus definition of probable 
DSP. We found that EDx testing changed the etiology and/or management in 2 of 366 patients 
(0.5%), and we provided detailed management changes for all patients.  
Evaluating the evidence, we conclude that the benefit of EDx testing is low in patients with DSP 
of known cause based on two studies that evaluated this clinical scenario.
2, 6
 Both studies 
conclude that EDx testing should not be routinely performed in this population. Importantly, 
these two studies were the largest and used the most precise case definitions. What remains 
unknown is which clinical factors should prompt EDx testing in patients with DSP. We have 
proposed that asymmetry, non-length dependence, motor predominance, and acute/subacute 
onset are likely important clinical factors. To move our field forward we need higher quality 
evidence — a prospective, adequately powered, multi-site study including community and 
academic settings, using precise inclusion criteria and documenting potential clinical factors that 
may indicate the need for EDx testing. Funding high quality studies to define the precise role of 
EDx testing in DSP should be a priority. 
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